What is the recommended management of a peptic ulcer, including H. pylori testing and appropriate therapy?

Management of Peptic Ulcer Disease

All patients with peptic ulcer disease should undergo H. pylori testing, and if positive, receive 14-day bismuth quadruple therapy or concomitant quadruple therapy as first-line eradication treatment. 1

H. Pylori Testing Strategy

Who to Test

• All patients with peptic ulcer disease (both gastric and duodenal ulcers) require H. pylori testing prior to discharge 1
• Empirical antimicrobial therapy without testing is not recommended 1
• Testing confirms infection before initiating eradication therapy, which is more appropriate than treating all patients empirically given variable regional prevalence (20-50%) 1

Testing Methods

Non-invasive testing options:

• Urea breath test (UBT): Sensitivity 88-95%, specificity 95-100% 1
• Stool antigen test: Sensitivity 94%, specificity 92% 1
• Both tests are acceptable first-line options for active infection 1

Important testing caveats:

• Withhold antibiotics and bismuth for at least 4 weeks before testing 1
• Withhold PPIs for at least 7 days before testing 1
• Patient should fast for at least 6 hours before UBT 1
• Serologic tests should only be used for initial diagnosis, never to confirm eradication, as antibodies remain elevated after treatment 1

Endoscopic testing:

• In bleeding peptic ulcer, H. pylori testing on endoscopic tissue biopsy is available 1

First-Line Eradication Therapy

Preferred Regimens (14 days duration)

Bismuth Quadruple Therapy (first choice):

• PPI standard dose twice daily
• Bismuth subsalicylate
• Tetracycline 500 mg four times daily
• Metronidazole 500 mg twice daily 1, 2

Concomitant Quadruple Therapy (non-bismuth alternative):

• PPI standard dose twice daily
• Clarithromycin 500 mg twice daily
• Amoxicillin 1000 mg twice daily
• Metronidazole 500 mg twice daily 1, 3, 2

Critical Treatment Principles

• Standard triple therapy (PPI + clarithromycin + amoxicillin) should only be used in areas with clarithromycin resistance <20% 1
• Treatment duration must be 14 days to achieve >90% eradication rates 1
• In bleeding peptic ulcer, start eradication therapy after 72-96 hours of IV PPI administration, when oral feeding is reintroduced 1

Second-Line Therapy After First-Line Failure

Levofloxacin-based triple therapy (10-14 days):

• PPI standard dose twice daily
• Levofloxacin 500 mg once daily (or 250 mg twice daily)
• Amoxicillin 1000 mg twice daily 1

Alternative if not previously used:

• Optimized bismuth quadruple therapy for 14 days 2

Important consideration:

• Levofloxacin or clarithromycin-containing regimens should only be used if antibiotic susceptibility is confirmed 2
• After two failed eradication attempts, culture and sensitivity testing should guide third-line therapy 1

Post-Treatment Management

Confirmation of Eradication

Mandatory test-of-cure in:

• All gastric ulcers 1
• Complicated peptic ulcer disease (bleeding, perforation) 1
• Gastric MALT lymphoma 1

Testing timing:

• Perform no earlier than 4 weeks after cessation of treatment 1
• Use UBT or stool antigen test (not serology) 1

Acid Suppression Duration

Uncomplicated duodenal ulcer:

• Prolonged PPI therapy not required after successful H. pylori eradication 1

Gastric ulcer and complicated duodenal ulcer:

• Continue PPI until complete healing is confirmed 1
• Endoscopic follow-up needed for gastric ulcers to exclude malignancy 1

Bleeding peptic ulcer:

• H. pylori eradication reduces rebleeding rate from 26% to near zero 1
• Eradication therapy is critical to prevent recurrent bleeding 1

Special Considerations

NSAID-Related Ulcers

• Discontinue NSAIDs if possible 4
• If NSAIDs cannot be discontinued, treat with PPIs 4
• Combination of H. pylori infection and NSAID use increases bleeding risk more than sixfold 5
• Eradicating H. pylori in NSAID users reduces peptic ulcer likelihood by 50% 5

Prevention in High-Risk Patients

• Patients with ulcer history on chronic NSAIDs: PPIs with or without celecoxib 4
• Patients with ulcer history on low-dose aspirin: PPIs or vonoprazan 4

Common Pitfall

The most critical error is using clarithromycin-based triple therapy empirically in regions with high clarithromycin resistance (>20%), which results in unacceptably low eradication rates 1, 2. Always use quadruple therapy (bismuth or concomitant) as first-line empiric treatment to reliably achieve >90% cure rates 3, 2.